Evidence-based approaches to penicillin allergy de-labelling
Neil Powell combines the roles of consultant antimicrobial pharmacist and clinical researcher at the Royal Cornwall Hospital in Truro. In this series of short videos, he describes the […]
Neil Powell combines the roles of consultant antimicrobial pharmacist and clinical researcher at the Royal Cornwall Hospital in Truro. In this series of short videos, he describes the […]
The work of a consultant antimicrobial pharmacist involves not only knowing about antimicrobial medicines but also understanding how people and organisations behave and collaborating with others to optimise […]
Implementation of penicillin allergy de-labelling calls for an understanding of the key barriers and enablers in healthcare systems – topics that the iNAAN and ALABAMA studies address, explains […]
The PALACE study showed that in people at low-risk of penicillin allergy, a direct oral challenge with penicillin was no less effective than standard allergy testing for determining […]
Neil Powell combines the roles of a consultant antimicrobial pharmacist and a clinical researcher at the Royal Cornwall Hospital in Truro. His current research is focused on the […]
Adequate levels of Vitamin D are critical for satisfactory immune function and this has stimulated interest in point-of-care testing (POCT) in community pharmacies. A pilot study has recently […]
The pilot study of pharmacist-led vitamin D point-of-care testing showed that the procedure was feasible in routine practice and, surprisingly, that more than half of participants had insufficient […]
Adequate levels of Vitamin D are critical for satisfactory immune function and this has stimulated interest in point-of-care testing (POCT) in community pharmacies. A pilot study has recently […]
STEP-HFpEF was a randomised, controlled trial designed to find out whether semaglutide for 52 weeks could improve heart failure symptoms and physical function in obese, non-diabetic patients with […]
The results of the STEP-HFpEF trial point towards routine use of GLP-1 agonists in heart failure but this has to be balanced against conflicting guidelines and cost pressures […]
The results of the STEP-HFpEF trial showed statistically significant benefits “across the board” and these benefits were not due to weight loss alone, according to Vicky Ruszala, Specialist […]
STEP-HFpEF was a randomised, controlled trial designed to find out whether semaglutide for 52 weeks could improve heart failure symptoms and physical function in obese, non-diabetic patients with […]